Where does Epizyme, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Epizyme, Inc. ranks #2,589 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Epizyme, Inc. hold?

Epizyme, Inc. holds 150 US utility patents granted between 2015 and 2025, spanning 16 technology areas.

What is Epizyme, Inc.'s Innovation Score?

Epizyme, Inc. has an Innovation Score of 47.3 out of 100 (top 19% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Epizyme, Inc.'s patent grant rate increasing or decreasing?

Epizyme, Inc.'s recent grant velocity is -55% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Epizyme, Inc.'s patents?

Epizyme, Inc.'s patents average 19.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Epizyme, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Epizyme, Inc.

Q: What technology areas does Epizyme, Inc. focus on?

Epizyme, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 133 patents. Grants appear in 16 CPC subclasses total.

USPTO PatentsView assignee record - 150 granted patents across 16 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Epizyme ranks #2,589 of 49,997 tracked US assignees by granted-patent volume, with 150 patents across 16 technology areas.

#2,589
of 49,997 US assignees by volume: Top 19%
by Innovation Score (47.3/100): 19.0
avg claims per patent: -55%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2589 · US Corporation #2,589 · 150 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MID 150 grants
TOP-DECILE #2,589/49,997
PHOTO-FINISH Auckland Uniservices
CPC-FOCUS A61P · 16 areas
INNOV-PAR 47.3/100
CLAIMS-RICH 19.0 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -55% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Auckland Uniservices Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Accton Technology · near

47
Epizyme · this assignee

47
Noble Systems · near

47
Nokia Shanghai Bell · near

47
Stradvision · near

47
3D Lighting… · lowest

7

What this shows Epizyme's Innovation Score is 47.3/100 (top 19% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Epizyme's grants concentrate

Epizyme, Inc. is a focused PatentsView assignee: 16 CPC subclasses with 88.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (26 grants) versus a trough of 4 in 2022. By volume, Epizyme sits between Auckland Uniservices Limited and Nextracker LLC.

Epizyme's three-year grant acceleration

From 2019–2021 to 2022–2024, Epizyme, Inc. moved from 38 to 25 grants (0.66x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,283. See the growth leaderboard.

Auckland Uniservi…

150
Canon Production…

150
Crowdstrike

150
Eberspächer Exhau…

150
Goodrich Lighting…

150
Harmonic Drive Sy…

150
Kyoraku

150
Nextracker

150
Epizyme ◀

150

What this shows Epizyme holds 150 patents at rank #2,589, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Epizyme

By rank, the assignees closest to #2,589 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Epizyme's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Epizyme, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (47 here).

Stradvision, Inc. 47 Noble Systems Corporation 47 Accton Technology Corporation 47 Nokia Shanghai Bell Co. Ltd. 47

Similar claim depth

Nearest assignees by average claims per patent (19.0 here).

Atlassian US, Inc. 19.0 avg Ascensia Diabetes Care Holdings AG 19.0 avg MicroStrategy Incorporated 19.0 avg SportsMEDIA Technology Corporation 19.0 avg

Epizyme's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 19% higher than 81% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Epizyme, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	19	12.7%
2016	19	12.7%
2017	26	17.3%
2018	22	14.7%
2019	17	11.3%
2020	11	7.3%
2021	10	6.7%
2022	4	2.7%
2023	12	8.0%
2024	9	6.0%
2025partial year	1	0.7%

Which technologies does Epizyme, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 133

C07D - Heterocyclic Compounds 120

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 101

Y02A - Technologies FOR Adaptation TO Climate Change 21

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 13

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 12

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 10

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 9

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 8

C12Y - Enzymes 5

C07K - Peptides 3

C07C - Acyclic OR Carbocyclic Compounds 2

Y10T - Technical Subjects Covered BY Former US Classification 2

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 1

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 1

Top 15 of 16 technology areas

Where it ranks

Overall rank by patents

#2,589

of 49,997 tracked assignees

Innovation Score

47.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Epizyme, Inc.'s patent record in context - here's where to go next.

Epizyme, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #2,589 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Epizyme, Inc. against Auckland Uniservices Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 47.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.